All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.

  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub
Brought to you by Scientific Education Support

The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

MPN Congress 2022

Share:

Oct 27, 2022

X post image

20 May 2023

Have you watched this yet?

During the 14th #MPNCongress2022, the MPN Hub was pleased to speak to Ann Mullally, Brigham and Women's Hospital, Boston, US. We asked, What is the use for monoclonal antibodies in MPN?

Watch the full video here 👇 #mpnsm
https://t.co/7S4lsGzJ7p

View on 

X post image

7 Dec 2022

#MPNCongress2022 | 🎥 The MPN Hub was pleased to speak to @mpdrc, UT Health San Antonio, San Antonio, US. We asked, How do symptoms inform treatment decisions in MPN?
Watch the full video here 👇
https://t.co/HFJnCTVwCI

View on 

X post image

14 Nov 2022

During the 14th #MPNCongress2022, the MPN Hub was pleased to speak to Ann Mullally, Brigham and Women's Hospital, Boston, US. We asked, What is the use for monoclonal antibodies in myeloproliferative neoplasms (MPN)?
Watch the full video here 👇 #mpnsm
https://t.co/7S4lsGAgWX

View on 

X post image

28 Oct 2022

RT @MeltonMedEd: Congratulations to this years abstract award winners! #MPNcongress2022

View on 

X post image

28 Oct 2022

#MPNCongress2022 | Key steps to change the paradigm of #MPN treatment by @RaajitRampal: 1- Identify which patients at higher risk of progression, 2- Intervene to prevent disease progression. See below some of the remaining Qs when designing new trials in this direction #mpnsm

View on 

X post image

28 Oct 2022

RT @MeltonMedEd: Day 1 of #MPNCongress2022 was a great success! #MPNsm

View on 

X post image

27 Oct 2022

#MPNCongress2022 | John Mascarenhas reviews new agents in clinical development for patients with #MF beyond JAKi. See below his take-home messages and new agents to keep an eye on👇 #mpnsm

View on 

X post image

27 Oct 2022

#MPNCongress2022 | The therapeutic landscape for #MPN is rapidly changing. Pemmaraju, @doctorpemm, focuses his talk on #MF and new combo therapies, highlightening the need to further explore the impact of early intervention and aim for OS and disease-modifying endpoints #mpnsm

View on 

X post image

27 Oct 2022

Congratulations to Hans Hasselbalch on receiving the Medical Excellence Award during the 14th International Congress on MPN #MPNCongress2022, for his livelong dedication to improving the lives of patients with #MPN #MPNsm

View on 

X post image

27 Oct 2022

#MPNcongress2022 | Angela Fleischman @MPNlab shares some strategies to target the inflammation in the microenvironment: pharmacologically, through the gut microbiome, & with nutrition intervention. In a pilot study, adhesion to a mediterranean diet reduced symptom burden #mpnsm

View on 

 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

MPN Congress 2022International Congress on Myeloproliferative Neoplasms

Your opinion matters

Do you include basal serum tryptase (bST) testing in the diagnostic evaluation of patients with MPN?

Newsletter

Subscribe to get the best content delivered to your inbox